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CASE REPORT
Severe acute respiratory syndrome 
coronavirus 2-induced acute aortic occlusion: 
a case report
Artem Minalyan*, Franklin L. Thelmo, Vincent Chan, Stephanie Tzarnas and Faizan Ahmed
Abstract 
Background: Severe acute respiratory syndrome coronavirus 2 infection can lead to a constellation of viral and 
immune symptoms called coronavirus disease 2019. Emerging literature increasingly supports the premise that 
severe acute respiratory syndrome coronavirus 2 promotes a prothrombotic milieu. However, to date there have been 
no reports of acute aortic occlusion, itself a rare phenomenon. We report a case of fatal acute aortic occlusion in a 
patient with coronavirus disease 2019.
Case report: A 59-year-old Caucasian male with past medical history of peripheral vascular disease presented to the 
emergency department for evaluation of shortness of breath, fevers, and dry cough. His symptoms started 5–7 days 
prior to the emergency department visit, and he received antibiotics in the outpatient setting without any effect. He 
was found to be febrile, tachypneic, and hypoxemic. He was placed on supplemental oxygen via a non-rebreather 
mask. Chest X-ray showed multifocal opacifications. Intravenous antibiotics for possible pneumonia were initiated. 
Hydroxychloroquine was initiated to cover possible coronavirus disease 2019 pneumonia. During the hospitalization, 
the patient became progressively hypoxemic, for which he was placed on bilevel positive airway pressure. D-dimer, 
ferritin, lactate dehydrogenase, and C-reactive protein were all elevated. Severe acute respiratory syndrome coro-
navirus 2 reverse transcription polymerase chain reaction was positive. On day 3, the patient was upgraded to the 
intensive care unit. Soon after he was intubated, he developed a mottled appearance of skin, which extended from 
his bilateral feet up to the level of the subumbilical plane. Bedside ultrasound revealed an absence of flow from the 
mid-aorta to both common iliac arteries. The patient was evaluated emergently by vascular surgery. After a discussion 
with the family, it was decided to proceed with comfort-directed care, and the patient died later that day.
Discussion: Viral infections have been identified as a source of prothrombotic states due to direct injury of vascular 
tissue and inflammatory cascades. Severe acute respiratory syndrome coronavirus 2 appears to follow a similar pat-
tern, with numerous institutions identifying elevated levels of thrombotic complications. We believe that healthcare 
providers should be aware of both venous and arterial thrombotic complications associated with coronavirus disease 
2019, including possible fatal outcome.
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Background
AAO is a very rare life-threatening condition associated 
with high mortality despite advances in surgical man-
agement, with a 30-day mortality rate of 21–52%. Saddle 
embolus, in situ thrombosis in the setting of severe ath-
erosclerotic disease, and occlusion of previous surgical 
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constructions (for example, stents, grafts) are considered 
the most common causes of AAO [1]. Abdominal aor-
tic aneurysm (AAA) is another condition that is known 
to be associated with an increased risk of AAO. It is 
thought that AAA can cause AAO as there is an inter-
ruption in laminar flow leading to turbulence and an 
increased risk of clot formation [2]. Multiple conditions 
including malignancies, infections, and connective tissue 
disorders are known to lead to hypercoagulability. There-
fore, patients with said conditions are also at increased 
risk of thrombotic events [3]. SARS-CoV-2 is the cause 
of the current 2019–2020 pandemic. There is emerging 
evidence that it is also associated with hypercoagulable 
states, therefore, leading to thrombotic events [4]. Arte-
rial thrombotic events have also been described in the lit-
erature [5, 6]. It is speculated that endovascular damage 
triggers the cascade of pathologic changes that leads to 
the development of arterial thrombi [7].
Case presentation
A 59-year-old Caucasian male presented to the emer-
gency department (ED) from a nursing home for evalu-
ation of shortness of breath, fevers, and dry cough. His 
past medical history included schizophrenia, epilepsy, 
and peripheral vascular disease. As per the patient, his 
symptoms started 5–7 days prior to the ED visit. He was 
treated in the outpatient setting with azithromycin for 
concern of community-acquired pneumonia. He pre-
sented to the ED due to progressive dyspnea from his 
facility where staff found the patient to be hypoxemic 
with an  O2 saturation in the 80s on room air. Of note, the 
patient was exposed to facility residents with confirmed 
SARS-CoV-2 infection. However, he tested negative for 
SARS-CoV-2 infection prior to arrival.
In the ED, he was found to be febrile with oral tem-
perature of 38.2 ℃, tachypnea at 22 breaths per minute, 
and persistent hypoxemia requiring supplemental oxy-
gen delivery via a non-rebreather mask. Physical exam 
revealed no aberrations in his heart or lungs. Chest X-ray 
showed bilateral airway opacities concerning for multifo-
cal pneumonia. A complete metabolic panel (CMP) and 
complete blood count (CBC) with differential revealed 
lymphopenia with an absolute lymphocyte count 0.5 K/
μL (reference range 1.5–3.2). The patient was started on 
intravenous antibiotics (vancomycin, cefepime, levo-
floxacin) for presumed bacterial pneumonia. Hydroxy-
chloroquine was initiated to cover possible COVID-19 
pneumonia. The patient was admitted to hospital. On 
day 2, the patient remained hypoxemic and developed 
increased work of breathing for which he was placed on 
bilevel positive airway pressure (BiPAP). D-dimer, ferri-
tin, lactate dehydrogenase, and C-reactive protein were 
all elevated (Fig.  1). SARS-CoV-2 reverse transcription 
polymerase chain reaction (RT-PCR) was positive. On 
day 3, the patient was upgraded to the intensive care unit 
(ICU) where he was later intubated. Soon after he was 
intubated, he developed a mottled appearance of skin 
that extended from his bilateral feet up to the level of the 
subumbilical plane. Pulses were unable to be detected 
both via palpation and Doppler. Bedside ultrasound was 
performed, and absence of anterograde flow was noted 
from the mid-aorta down to both common iliac arter-
ies (Fig. 2); a deep venous thrombosis (DVT) in the left 
femoral vein was also revealed. The patient became hypo-
tensive in the ICU with mean arterial pressure (MAP) of 
50 mmHg. He was started on a norepinephrine drip for 
pressure support. Given hemodynamic instability and 
the high likelihood of venous thromboembolic event, the 
decision was made to start thrombolytic therapy with tis-
sue plasminogen activator (tPA) of 50 mg intravenously 
once as well as systemic anticoagulation with a heparin 
drip. The patient was evaluated emergently by the vascu-
lar surgery team. The patient was deemed too unstable 
to be taken for computed tomography (CT) angiography. 
No AAA was identified in the patient. After a discussion 
with the family, it was decided to proceed with comfort-
directed care, and the patient died later that day.
Discussion and conclusions
SARS-CoV-2, first reported in Wuhan, China on 31 
December 2019, is a virus that has caused a pandemic 
as declared by the World Health Organization (WHO) 
in March 2020 [8, 9]. As of mid-May, there are almost 
4,500,000 reported cases worldwide while the USA has 
Fig. 1 Trends of inflammatory markers during hospitalization
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the highest number of cases (almost 1,500,000). It is 
estimated that at least 300,000 people have died so far 
because of COVID-19 [10]. SARS-CoV-2 belongs to 
the genus Betacoronavirus [11]. There are four lineages 
within the genus: A (HCoV-OC43, HCoV-HKU1)—fre-
quently found in patients with common cold; B (SARS-
CoV and SARS-CoV-2)—cause of SARS and COVID-19 
pandemics, respectively; C (Middle East respiratory 
syndrome-related coronavirus (MERS-CoV)—cause of 
MERS outbreak; D (CoV-HKU9)—found only in ani-
mals [12]. They are all enveloped positive-sense single-
stranded ribonucleic acid (RNA) viruses. Notably, both 
SARS-CoV and SARS-CoV-2 use the same receptor, 
angiotensin-converting enzyme 2 (ACE2), for cell entry 
[13]. It is estimated that SARS-CoV-2 is more conta-
gious than seasonal influenza on the basis of their differ-
ing R0 values, with influenza being estimated at 1.3 and 
SARS-CoV-2 being estimated at 2.5 [14, 15]. The major-
ity of patients with COVID-19 have nonsevere symp-
toms and do not require hospitalization. In hospitalized 
patients, it has been shown that about 15% of patients 
are treated in the ICU. Importantly, in a study from New 
York, 12% of hospitalized patients were reported to be 
placed on mechanical ventilation. In ventilated patients, 
the survival was found to be only 12% [16]. Despite the 
availability of several therapeutic agents being studied 
for COVID-19, all remain investigational, and support-
ive treatment is considered the therapeutic mainstay in 
affected patients.
Various infections have been known to be associated 
with an increased risk of thrombosis. There are several 
possible explanations of thrombosis in infections: (1) 
activation of platelets, (2) shift of the coagulation cas-
cade towards procoagulant state, (3) stasis in the setting 
of prolonged immobilization, and (4) vascular endothelial 
dysfunction. The above-mentioned changes are consist-
ent with Virchow’s triad, which is widely recognized as 
the pathophysiological foundation of venous thrombosis 
formation [17]. It is suggested that the inflammation-
induced thrombosis from an infectious trigger has more 
Fig. 2 Ultrasound Doppler imaging of patient’s aorta and iliac arteries (a) proximal aorta, (b) mid aorta, (c) left common iliac artery, and (d) right 
common iliac artery
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procoagulant potential when compared with noninfec-
tious inflammatory conditions. Viral models in animals 
of infections such as Ebola, influenza, and human immu-
nodeficiency virus (HIV) have shown that viruses can 
induce the expression of tissue factor in phagocytes that 
in turn activate the extrinsic pathway of the coagulation 
cascade [18]. The activation of macrophages has been 
shown to induce deposition of fibrin in multiple organs 
[19]. In addition, in mice infected with a lethal dose of 
influenza virus leading to acute respiratory distress syn-
drome (ARDS), increased platelet aggregation, endothe-
lial damage, and release of inflammatory cytokines 
manifesting as the presence of diffuse pulmonary micro-
vascular thrombi have been observed [20].
In patients with COVID-19, it was estimated that up to 
a third of critically ill patients develop thromboembolic 
events [21]. Interestingly, life-threatening thrombosis 
has been noted to occur frequently in affected patients 
despite full-dose anticoagulation [22]. In all hospitalized 
patients with COVID-19, multiple laboratory tests are 
obtained initially. High fibrinogen and D-dimer can be 
indicative of procoagulant state. Fibrinogen (factor I) is 
a plasma protein involved in both primary and second-
ary hemostasis. Of note, there is some evidence that very 
high levels of fibrinogen can act as antithrombin and, 
therefore, compromise clot stability [23]. D-dimer is a 
protein fragment that is formed after the degradation of 
factor XIIIa cross-linked fibrin. It is cleared in the liver 
and spleen. Therefore, in patients with asplenia and liver 
failure, D-dimer can circulate in blood for a prolonged 
time [24]. Detection of normal levels of D-dimer is help-
ful in ruling out venous thromboembolism (VTE). In 
contrast, high levels of D-dimer are nonspecific and can 
be seen in patients with VTE as well as malignancy, sep-
sis, and other inflammatory conditions. It was reported 
that patients with very high levels of D-dimer (>  5000 
µg/L) have high predictive value for serious disease, 
including VTE (40.1%), cancer (28.9%), sepsis (24.4%), 
and complicated trauma/surgery (24.4%) [25]. Imag-
ing tests [bilateral compression ultrasonography of the 
legs and CT pulmonary angiography (CTPA)] are diag-
nostic tests of choice in patients with suspected VTE. 
In patients hospitalized with COVID-19, imaging tests 
such as CTPA may not always be readily available given 
healthcare strain due to the ongoing pandemic. There-
fore, quantitative assessment of D-dimer is widely used 
to assess the risk of VTE and initiate empiric treatment 
with anticoagulation in high-risk patients. Of note, there 
are no universally accepted guidelines on D-dimer trends 
and the decision on anticoagulation in affected patients. 
Those decisions are mostly made based on physician dis-
cretion and hospital protocol.
In general, AAO is an extremely rare condition. Its true 
incidence is unknown, with numbers being obtained 
from case series. This is in contrast to arterial thrombo-
sis leading to acute limb ischemia with an incidence rate 
of 1.5 per 100,000 person-years [26]. In 2019 the Swed-
ish Nationwide Vascular Database reviewed patients with 
AAO from 1994 to 2014 and estimated an incidence rate 
of 3.8 per 1 million person-years, with the average indi-
vidual being 70 years of age, presenting with acute limb 
ischemia with a history of cardiac disease, hypertension, 
and current smoking [1]. Le Berre et al reported a nonfa-
tal case of acute aortic thrombosis in a 71-year-old male 
with COVID-19. A CT angiogram of the aorta revealed 
an accidental finding of a free-floating thrombus in the 
descending aorta. The patient was treated with thera-
peutic enoxaparin [6]. While our case likely highlights 
the first reported case of SARS-CoV-2-induced AAO, the 
association between viral infection and arterial thrombi 
has been previously identified [27, 28]. Unlike venous 
thromboembolic events proposed to be mostly related 
to hemostasis and coagulopathy, it has been postulated 
that arterial thrombus is driven more so by endovascular 
injury rather than stasis given the dynamic nature of the 
arterial wall [7].
Treatment options for acute arterial thrombo-
sis include anticoagulation, thrombolysis, mechani-
cal thromboembolectomy, and clot bypass. The choice 
of therapy depends on the timing and the setting of the 
artery involved, such as a coronary artery or a cerebral 
artery. Acute treatment with thrombolytics that cause 
the degradation of fibrin such as tPA is one such example 
where the timing of arterial thrombosis is crucial in its 
use [29]. Other common medical therapies include anti-
platelet agents such as cyclooxygenase inhibitors, P2Y12 
inhibitors, glycoprotein IIb/IIIa inhibitors, and protease-
activated receptor 1 inhibitors [30]. Newer studies are 
beginning to investigate the utility of direct oral antico-
agulants such as apixaban and rivaroxaban in peripheral 
arterial disease and other arterial thromboses [31, 32].
Acute aortic thrombosis, as compared with coronary, 
cerebral, and peripheral arterial thrombosis, is rare. 
There are no specific guidelines on management of acute 
aortic thrombosis as literature is mostly relegated to case 
reports.
In summary, the nascent COVID-19 pandemic has 
raised global concern regarding the role of viral infec-
tion and its effect on hypercoagulability. There is ongoing 
debate as to whether individuals should be actively moni-
tored for severe thromboembolic events due to COVID-
19 and if the initiation of therapeutic anticoagulation is 
warranted. Our case demonstrates that life-threatening 
hypercoagulability of large arterial vessels leading to 
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occlusion can develop in patients with COVID-19, lead-
ing to hemodynamic collapse.
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